Abstract | INTRODUCTION: AREAS COVERED: This review covers the current evidence on antiplatelet therapy for patients with non- cardioembolic stroke or TIA. Randomized controlled trials of antithrombotic strategies for patients with these conditions were searched in Pubmed/Medline from 1970 to 2022. EXPERT OPINION:
|
Authors | Lorenzo Scalia, Dario Calderone, Davide Capodanno |
Journal | Expert review of clinical pharmacology
(Expert Rev Clin Pharmacol)
Vol. 15
Issue 9
Pg. 1027-1038
(Sep 2022)
ISSN: 1751-2441 [Electronic] England |
PMID | 36031827
(Publication Type: Journal Article, Review)
|
Chemical References |
- Anticoagulants
- Fibrinolytic Agents
- Platelet Aggregation Inhibitors
- Dipyridamole
- Factor XI
- Clopidogrel
- Ticagrelor
- Aspirin
|
Topics |
- Anticoagulants
- Aspirin
(adverse effects)
- Clopidogrel
(adverse effects)
- Dipyridamole
(adverse effects)
- Drug Therapy, Combination
- Factor XI
(therapeutic use)
- Fibrinolytic Agents
(therapeutic use)
- Hemorrhage
(chemically induced)
- Humans
- Ischemic Attack, Transient
(drug therapy, epidemiology, prevention & control)
- Ischemic Stroke
- Platelet Aggregation Inhibitors
(adverse effects)
- Stroke
(drug therapy, etiology, prevention & control)
- Ticagrelor
(therapeutic use)
|